- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Novo Nordisk not currently in a position to pursue large-scale M&A, CEO says | ||
| Mi | What is 'Premium Content' on Pharmaceutical Technology? | ||
| Mi | Mironid banks $46m in Series B to take rare kidney disease drug closer to clinic | ||
| Mi | AsymBio to secure $184m to support growth in biologics manufacturing | ||
| Mi | Phylo and Chugai collaborate to deploy AI platform in drug discovery | ||
| Di | Pfizer repels Covid-19 sales tumble to raise 2026 guidance | ||
| Di | Supernus and Indivior merge to create scaled, CNS-focused entity | ||
| Di | FDA grants breakthrough therapy designation to Lilly's olomorasib | ||
| Di | Curium to acquire Lantheus in all-cash deal worth up to $8bn | ||
| Mo | Amgen contends with data breach, exposing patient information | ||
| Mo | AstraZeneca shares slump after $400bn BMS merger rumours | ||
| Mo | IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib | ||
| Mo | Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy | ||
| Fr | Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns | ||
| Fr | J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout | ||
| Fr | miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies | ||
| Fr | Resilience and Lilly to increase US medicines production with $750m investment | ||
| 30.07. | Pfizer seeks label expansion for Litfulo after double Phase III NSV win | ||
| 30.07. | EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals | ||
| 30.07. | FDA AdCom shuns Capricor's DMD cell therapy amid data dispute | ||
| 30.07. | The $1.2tn untapped pharma opportunity in tropical conservation | ||
| 30.07. | Amgen's Repatha receives positive CHMP opinion for broader cardiovascular use | ||
| 30.07. | Synlogic and Caldera sign merger agreement | ||
| 29.07. | AdCom expected for uniQure's Huntington's gene therapy, chief medical officer says | ||
| 29.07. | GSK eyes future growth with cost-cutting plan amid promising Q2 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.